Prodrugs of CC-1065 analogs

Details Prodrugs of CC-1065 analogs Prodrugs of CC-1065 analogs

2011-03-15

2011-03-15

Shiao, Rei-tsang (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S427000, C424S085400

Reexamination Certificate

active

07906545

ABSTRACT:
Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.

REFERENCES:
patent: 5070092 (1991-12-01), Kanda et al.
patent: 5475092 (1995-12-01), Chari et al.
patent: 5585499 (1996-12-01), Chari et al.
patent: 5843937 (1998-12-01), Wang et al.
patent: 5846545 (1998-12-01), Chari et al.
patent: 6060608 (2000-05-01), Boger
patent: 6534660 (2003-03-01), Chari et al.
patent: 6548530 (2003-04-01), Boger
patent: 6586618 (2003-07-01), Zhao et al.
patent: 2003/0195365 (2003-10-01), Zhao et al.
patent: 2009/0028821 (2009-01-01), Zhao et al.
patent: 97/44000 (1997-11-01), None
patent: 03/087055 (2003-10-01), None
Chari, et al., “Enhancement of the selectivity and antitumor efficacy of a CC-1065 analog through immunoconjugate formation”, Cancer Research, vol. 55, No. 18, pp. 4079-4084, 1995.
Katsushige Gomi, et al., “Anticellular and Antitumor Activity of Duocarmycins, Novel Antitumor Antibiotics,” Jpn. J. Cancer Research, Jan. 1992, pp. 113-120, vol. 83.
Chong-Soon Lee, et al., “Determination of the Structural Features of (+) -CC-1065 That Are Responsible for Bending and Winding of DNA,” Chem. Res. Toxicol., 1991, pp. 203-213, vol. 4, No. 2.
David H. Swenson, et al, “Evaluation of DNA Binding Characteristics of Some CC-1065 Analogs,” Chem.-Biol. Interactions, 1988, pp. 199-213, vol. 67.
Li H. Li, et al., “Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065,” Investigational New Drugs, 1991, pp. 137-148, vol. 9, No. 2.
Bruce W. Ennis, et al., “The EGF Receptor System as a Target for Antitumor Therapy,” Cancer Investigation, 1991, pp. 553-562, vol. 9, No. 5.
Magda C. Gutowski, et al., “Epidermal Growth Factor Receptor-reactive Monoclonal Antibodies: Xenograft Antitumor Activity Alone and as Drug Immunoconjugagtes,” Cancer Res. 1991, pp. 5471-5475, vol. 51, No. 20.
Dale L. Boger, et al., “Parallel Synthesis and Evaluation of 132 (+)-1, 2, 9, 9aTetrahydrocyclopropa[c] benz [e] indol -4 -one (CBI Anaologues of CC-1065 and the Duocarmycins Defining the Contribution of the DNA-Binding Doman,” Journal of Organic Chemistry, 2001, 66(20), 6654-6661. (abstract).
Yuqiang Wang, “Synthesis and Preliminary Biological Evaluations of CC-1065 Analogues: Effects of Different Linkers and Terminal Amides on Biological Activity,” Journal of Medicinal Chemistry (2000), 43(8), 1541-1549.
European Office Action issued Apr. 4, 2007, in EP03714044.9.
Dale L. Boger et al., “CBI Prodrug Analogs of CC-1065 and the Duocarmycins,” Synthesis, no S.I., 1999, 1505-1509.
Alex Sparreboom et al., “Irinotecan (CPT-11) Metabolism and Disposition in Cancer Patients,” Clinical Cancer Research, 1998, 4:2747-2754.
Scot Z. Fields et al., “Phase I Study of Etoposide Phosphate (Etopophos) as a 30-Minute Infusion on Days 1, 3, and 5,” Clinical Cancer Research, 1995, 1:105-111.
International Search Report in International Application No. PCT/US03/07282 dated Feb. 8, 2007.
Wang, Y., et al., “Synthesis and cytotoxicity of a biotinylated CC-1065 analogue”, BMC Chemical Biology, Biomed Central, London, vol. 2, No. 1, pp. 1-4, Jan. 28, 2002.
European Search Report dated Sep. 6, 2010, as issued in European Application No. 10006198.5.

Affiliated with

Also associated with

Rating

Prodrugs of CC-1065 analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs of CC-1065 analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of CC-1065 analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2669458